Wynnewood, Pa. (September 4, 2013) – LIMR Chemical Genomics Center, Inc. (LCGC) announced they have achieved a second milestone in a research collaboration with Dynamis Therapeutics, Inc. for discovery of new drug leads. The program at LCGC continues to focus on the fructosamine-3-kinase (FN3K) enzyme as a target for developing new treatments for complications of both Type I and Type II diabetes.
“We are delighted to continue working with the Dynamis team on the FN3K enzyme which is a highly innovative target for drug development in diabetes,” notes Melvin Reichman, PhD, president and founder of LCGC. “Our work holds promise for treating all of the most common complications of this increasingly prevalent and debilitating disease.” The company’s proprietary technologies accelerated by 500% the screening of hundreds of thousands of diverse, drug-like molecules owned by LCGC in the definition of drug leads.
“This program is an ideal match between Dynamis’ innovative technologies to treat diabetes complications and inflammation and LCGC’s unique center of excellence in drug discovery support,” states Annette M. Tobia, PhD, JD, founder and CEO of Dynamis Therapeutics. “Our joint research will advance new therapies to the clinic for treating diabetic nephropathy and other diabetes complications.”
Dynamis will continue to provide sponsored funding for LCGC to continue research in support of drug candidate optimization. The research was also supported by NIH grants from the National Institute of Diabetes and Digestive and Kidney Diseases (R43DK088407, SBIR) and the National Institute of Neurological Disorders and Stroke (R21NS061706).
About LIMR Chemical Genomics Center, Inc. (LCGC)
LCGC’s business model is a protected open-innovation framework called Double-Blinded Drug DiscoveryTM, which establishes a new public-private partnering paradigm. The LCGC compound library is stored in a patented NanoTube Automated Repository System (NARS) that can manage 10 million compounds using a robot working in a room-sized freezer housed on campus. The system preserves chemical and biological materials, while allowing for their rapid access for testing. The company is working with almost two dozen universities, research institutes and private companies worldwide to support drug discovery research. LCGC is a for-profit biotech wholly owned by Lankenau Institute for Medical Research (LIMR), an independent, non-profit biomedical research center located in suburban Philadelphia on the campus of Lankenau Medical Center, part of Main Line Health. LCGC was founded by Melvin Reichman, PhD, and George C. Prendergast, PhD. To learn more about LCGC, visit lcgcinc.com.
About Dynamis Therapeutics, Inc.
Dynamis Therapeutics, Inc. (Jenkintown, PA) has proprietary drug candidates in preclinical development that selectively inhibit a novel signaling pathway catalyzed by the fructosamine-3-kinase (FN3K) enzyme. The FN3K enzyme initiates inflammation associated with hyperglycemia by triggering the formation of 3-deoxyglucosone (3DG). Research conducted by the company’s founding scientists at Fox Chase Cancer Center, and confirmed by other researchers independently, indicates that prolonged hyperglycemia causes the accumulation of 3DG and is involved in the progression of diabetic complications. Evidence is emerging that this metabolic pathway is involved in the development of Alzheimer’s disease. Annette M. Tobia, PhD, JD, is the founder and CEO of Dynamis. She has raised over $10 million in equity financing, licensing fees, government grants and other instruments. For more information, please contact us through our webpage at dynamis-therapeutics.com.
Help employers find you! Check out all the jobs and post your resume.
